Intel stock spikes after report of possible US government stake
Investing.com - JMP analyst lowered the price target on AMN Healthcare Services (NYSE:AMN) to $22.00 from $33.00 on Thursday, while maintaining a Market Outperform rating following the company’s second-quarter earnings report. The healthcare staffing company, currently valued at $632 million, has seen its stock decline significantly over the past year according to InvestingPro data, though analysis suggests the stock may be undervalued at current levels.
AMN Healthcare reported revenue of $658.2 million for the second quarter of 2025, representing an 11% year-over-year decline. The results exceeded JMP’s estimate of $647.1 million and the consensus forecast of $652.1 million.
The healthcare staffing company posted EBITDA of $58.3 million, down 38% year-over-year, but surpassing JMP’s projection of $51.5 million and the consensus estimate of $52.2 million.
Gross margin came in at 29.8%, which increased 120 basis points sequentially and exceeded the high-end of AMN’s guidance range of 28.5-29.0%.
The company has delivered an average revenue surprise of 3% and an EBITDA surprise of 12% over the past four quarters, according to JMP’s analysis.
In other recent news, AMN Healthcare reported impressive second-quarter 2025 earnings, with earnings per share (EPS) of $0.30, significantly surpassing the forecasted $0.18. The company’s revenue also exceeded expectations, reaching $658.18 million compared to the projected $652.63 million. Despite these strong financial results, AMN Healthcare experienced a net loss, which seemed to weigh on investor sentiment. Following the earnings report, BMO Capital lowered its price target for AMN Healthcare from $27 to $22, while maintaining an Outperform rating. The adjustment in the price target reflects the company’s performance, with BMO Capital noting stronger margins despite softer volumes. These developments come amid broader market uncertainties affecting the healthcare staffing sector. The recent earnings call highlighted the company’s ability to exceed consensus estimates, driven primarily by improved margins.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.